1. Home
  2. AEMD vs ARTL Comparison

AEMD vs ARTL Comparison

Compare AEMD & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$2.13

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$8.82

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEMD
ARTL
Founded
1984
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.5M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
AEMD
ARTL
Price
$2.13
$8.82
Analyst Decision
Hold
Hold
Analyst Count
1
2
Target Price
$15.00
N/A
AVG Volume (30 Days)
62.4K
5.6M
Earning Date
02-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.85
52 Week High
$5.89
$28.60

Technical Indicators

Market Signals
Indicator
AEMD
ARTL
Relative Strength Index (RSI) 50.17 62.56
Support Level $1.86 $6.99
Resistance Level $2.79 $10.55
Average True Range (ATR) 0.20 2.26
MACD 0.04 0.34
Stochastic Oscillator 70.43 34.59

Price Performance

Historical Comparison
AEMD
ARTL

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: